This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pirmohamed M, Park K . Mechanism of clozapine-induced agranulocytosis. CNS Drugs 1997; 7: 139–158.
US Food and Drug and Administration (2015). FDA Drug Safety Communication: FDA modifies monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines. Available at http://www.fda.gov/Drugs/DrugSafety/ucm461853.htm.
Crilly J . The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007; 18: 39–60.
Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I . Letter: clozapine and agranulocytosis. Lancet 1975; 2: 611.
Kane J, Honigfeld G, Singer J, Meltzer H . Clozapine for the treatment resistant schizophrenic: a double–blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
Honigfield G . Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52–56.
Sriretnakumar V, Huang E, Muller D . Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert Opin Drug Metab Toxicol 2015; 11: 1709–1731.
Flanagan RJ, Dunk L . Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23: 27–41.
Comacchio C, Dusi N, Lasalvia A . Successful use of single doses of granulocyte-colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report. J Clin Psychopharmacol 2016; 36: 173–174.
Rajagopal S . Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 2005; 81: 545–546.
Manu P, Sarpal D, Muir O, Kane JM, Correll CU . When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180–186.
Gerson SL, Gullion G, Yeh HS, Masor C . Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet 1992; 340: 1097.
Hägg S, Rosenius S, Spigset O . Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003; 18: 173–174.
Hazewinkel AW, Bogers JP, Giltay EJ . Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis. Gen Hosp Psychiatry 2013; 35: 576.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Bastiampillai, T., Gupta, A., Chan, S. et al. Changes for clozapine monitoring in the United States. Mol Psychiatry 21, 858–860 (2016). https://doi.org/10.1038/mp.2016.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2016.66